Letter by Pirera Et Al Regarding the Paper "Direct Oral Anticoagulants in Embolic Stroke of Undetermined Source: an Updated Meta-analysis" by Marinheiro and Colleagues
Overview
Overview
Journal
J Thromb Thrombolysis
Specialty
Cardiology & Vascular Diseases
Date
2024 Dec 5
PMID
39633220
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Marinheiro G, Araujo B, Rivera A, de Almeida Monteiro G, Santana L, Leite M
. Direct oral anticoagulants in embolic stroke of undetermined source: an updated meta-analysis. J Thromb Thrombolysis. 2024; 57(7):1163-1171.
DOI: 10.1007/s11239-024-03017-7.
View
2.
Hart R, Sharma M, Mundl H, Kasner S, Bangdiwala S, Berkowitz S
. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018; 378(23):2191-2201.
DOI: 10.1056/NEJMoa1802686.
View
3.
Diener H, Sacco R, Easton J, Granger C, Bernstein R, Uchiyama S
. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019; 380(20):1906-1917.
DOI: 10.1056/NEJMoa1813959.
View
4.
Geisler T, Keller T, Martus P, Poli K, Serna-Higuita L, Schreieck J
. Apixaban versus Aspirin for Embolic Stroke of Undetermined Source. NEJM Evid. 2024; 3(1):EVIDoa2300235.
DOI: 10.1056/EVIDoa2300235.
View
5.
Kamel H, Longstreth Jr W, Tirschwell D, Kronmal R, Marshall R, Broderick J
. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial. JAMA. 2024; 331(7):573-581.
PMC: 10851142.
DOI: 10.1001/jama.2023.27188.
View